Wang HL, et al. KRAS mutation testing in human cancers: the pathologist’s role in the era of personalized medicine. Adv Anat Pathol 2010;17:23-32
Whitehall V, et al. A Multicenter blinded study to evalu- ate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009;11:543-552
Lièvre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26: 374-379
Amado RG. Wild-type KRAS is required for panitumu- mab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634
Allegra CJ, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carci- noma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-2096
Monzon FA, et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009;133:1600-1606
